ClinicalTrials.gg
CompletedNCT00378599Updated Apr 6, 2017Results posted

Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)

A Phase 3 interventional study of Combination of (a) pegylated interferon alfa-2b and (b) rebetol in Liver Transplantation, Hepatitis C, Chronic and Liver Cirrhosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.

Enrollment
14th of 39
125 · median 99
Started
2006
with 5 others
Phase 3
22 of 40
none open now
Registered
14th of 40
by date
Lead sponsor
25 of 40
Merck Sharp & Dohme LLC

Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 14th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2006, is one of 22 in phase 3, and was the 14th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2b

peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic as a file.
02

Study summary

This is an exploratory study and is a Phase 3, single-arm, multi-center, open-label study of pegylated interferon alfa-2b, PEG-IFN alpha-2b (PEG-Intron) and ribavirin (RBV) to determine the sustained virologic response (SVR) at 24-week follow-up to 48 week in subjects after orthotopic liver transplantation (OLT) with chronic hepatitis C (HCV) recurrence.

03

Conditions studied

  • Liver Transplantation
  • Hepatitis C, Chronic
  • Liver Cirrhosis
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must confirm that all prior medication washout times have been observed.
  • Subject must be 18 - 70 years of age of either gender and of any race.
  • Subject must be transplanted for end-stage or fulminant hepatitis C.
  • Subject must have documented:

    • persistent HCV viremia after OLT as defined by plasma positive for HCV RNA by quantitative reverse transcription-polymerase chain reaction (RT-PCR),
    • A liver transplant performed at least 3 months prior to screening but not more than 3 years prior to screening.
  • Subject must be on stable doses of for at least 1 month.
  • Compensated liver disease with minimum hematologic, biochemical, and serologic criteria at the (Day 1) baseline visit.

    • Alpha-fetoprotein value (AFP) less than or equal to 250ng/mL. If AFP greater than 100 ng/mL, patient will need evidence of normal liver (magnetic resonance imaging) MRI and normal chest computerized tomography (CT) scan within the last 3 months or during the screening period.
  • For subjects with a history of diabetes or hypertension, clearance from an ophthalmologist has to be obtained prior to treatment start (Day 1/Visit 2).
  • Subjects with a history of mild depression may be considered for entry into this study.
  • Female subjects cannot be pregnant or breastfeeding and must be either , surgically sterile or using 2 methods of .
  • Sexually active male subjects are practicing an acceptable, method of contraception.
  • Contraceptive measures will be reviewed with female subjects at each visit. Dual methods of contraception must be used for 1 month prior to the start of treatment and 6 months after treatment discontinuation.
  • Pregnancy tests obtained at Screen Visit and Day 1 Visit prior to the initiation of treatment must be negative.

Exclusion criteria

Exclusion Criteria:

  • Pregnant women, women who plan to become pregnant, male subjects whose partner wants to become pregnant, and breastfeeding women (during study and up to 6 months after study completion).
  • Subject has used any product within 30 days prior to Screening or is participating in any other clinical study.
  • Prior treatment for chronic post-liver transplant, including but not limited to antiviral or immunomodulatory product, any interferon product, or RBV, either as monotherapy or in combination.
  • Subjects with other organ transplants.
  • Any subject who received a positive hepatitis C core antibody () or HCV positive donor liver graft.
  • Retransplantation of the liver for rejection or graft failure.
  • Evidence of decompensated liver disease.
  • Known coagulopathies including hemophilia.
  • Known hemoglobinopathies.
  • Known glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • to alpha interferon and/or RBV.
  • Co-infection with hepatitis B virus (HBV) and/or (HIV).
  • Evidence of active or suspected or a history of malignancy within the last 5 years (with the exception of pre-transplant hepatocellular carcinoma histologically within the Milan criteria, and adequately treated basal or squamous cell carcinoma of the skin).
  • Any known pre-existing medical condition that could interfere with the subject's participation in and completion of the study.
  • Subject is or was a substance abuser. Subjects treated with buprenorphine (Subutex) who have been stable for 6 months may be included.
  • Patients weighing over 135 kg;

Is participating in any other clinical study(ies);

Is allergic to or has sensitivity to the study drug or its .

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    PEG-Intron plus Rebetol (RBV)

    PEG-Intron plus RBV treatment for up to 48 weeks with 24-week follow up. SCH 54031 PEG-Intron 1.5 ug/kg SC per week plus SCH 18908 REBETOL twice daily (BID) PO with food, dosed as followed: Weeks 1 and 2, RBV Dose 400 mg (2 capsules, 1 AM and 1 PM). At the end of Weeks 2 and 4 of Treatment (tx), a complete blood count (CBC) was performed. An increase in RBV dose was permitted only if the hemoglobin was \>10 g/dL. At Weeks 3 and 4, RBV dose was 800 mg (4 capsules, 2 AM and 2 PM). From Weeks 5 to 48, RBV doses could be increased based on subject body weight. For subjects weighing \<65 kg, maximum dose of RBV was to be 800 mg (4 capsules, 2 AM and 2 PM), for subjects weighing 65-85 kg, max dose of RBV was 1000 mg/day (5 capsules, 2 AM and 3 PM), for subjects weighing \>85 kg, max dose of RBV was 1200 mg/day, 6 capsules, 3 AM and 3 PM).

    Drug: Combination of (a) pegylated interferon alfa-2b and (b) rebetol

Interventions

  • DrugCombination of (a) pegylated interferon alfa-2b and (b) rebetol

    Drug pages: Peginterferon alfa-2b · Ribavirin

    1. Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks 2. 200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks

    Also known as: (a) SCH 54031, PEG-Intron, (b) SCH 18908, Rebetol

06

What researchers measure

Primary outcomes

  1. A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment

    Number of participants with SVR at 24-week follow up after treatment with PEG-Intron and Ribavirin in post-orthotopic liver transplant recipients with recurrent HCV.

    Time frame: 24 weeks after completion of up to 48 weeks of therapy

07

Results

Posted Jul 16, 2010

Participant flow

Participant flow — Overall Study
MilestonePEG-Intron Plus Ribavirin
Started125
Completed73
Not completed52
Withdrew: Adverse event38
Withdrew: Protocol violation2
Withdrew: Treatment failure7
Withdrew: Withdrawal by subject5

Outcome measures

PrimaryA Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment

Number of participants with SVR at 24-week follow up after treatment with PEG-Intron and Ribavirin in post-orthotopic liver transplant recipients with recurrent HCV.

Time frame:
24 weeks after completion of up to 48 weeks of therapy
Reported as:
Number · Participants
A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment
ParticipantsPEG-Intron Plus Ribavirin
A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment36 (21.1 to 37.6)
Statistical analysis
  • PEG-Intron Plus Ribavirin · Binomial approximation: .288 · 95% CI 0.21 to 0.38

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Interferon Alfa-2b and Ribavirin—32/125 (25.6%)125/125 (100%)
Most frequent serious events
Showing 10 of 49
Most frequent serious events
EventPegylated Interferon Alfa-2b and Ribavirin
ANAEMIABlood and lymphatic system disorders5/125
PNEUMONIAInfections and infestations4/125
VOMITINGGastrointestinal disorders3/125
CHEST PAINGeneral disorders3/125
CELLULITISInfections and infestations3/125
DEHYDRATIONMetabolism and nutrition disorders3/125
HEADACHENervous system disorders3/125
LEUKOPENIABlood and lymphatic system disorders2/125
THROMBOCYTOPENIABlood and lymphatic system disorders2/125
DIARRHOEAGastrointestinal disorders2/125
Most frequent other events
Showing 10 of 54
Most frequent other events
EventPegylated Interferon Alfa-2b and Ribavirin
ANAEMIABlood and lymphatic system disorders91/125
FATIGUEGeneral disorders89/125
HEADACHENervous system disorders79/125
NAUSEAGastrointestinal disorders59/125
DIARRHOEAGastrointestinal disorders51/125
NEUTROPENIABlood and lymphatic system disorders39/125
INSOMNIAPsychiatric disorders39/125
PYREXIAGeneral disorders35/125
DECREASED APPETITEMetabolism and nutrition disorders33/125
VOMITINGGastrointestinal disorders32/125

Baseline characteristics

Age, Continuous
Age, Continuous(years)PEG-Intron Plus Ribavirin
Mean54.2 ± 5.7
Sex: Female, Male
Sex: Female, Male(Participants)PEG-Intron Plus Ribavirin
Female19
Male106
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Gordon FD, Kwo P, Ghalib R, Crippin J, Vargas HE, Brown KA, Schiano T, Chaudhri E, Pedicone LD, Brown RS Jr. Peginterferon-alpha-2b and ribavirin for hepatitis C recurrence postorthotopic liver transplantation. J Clin Gastroenterol. 2012 Sep;46(8):700-8. doi: 10.1097/MCG.0b013e31825833be. PubMed 22739223 ↗

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2006
First posted
Sep 20, 2006
Start
May 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Results first posted
Jul 16, 2010
Last update
Apr 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00378599
Responsible party
Sponsor
First posted
Sep 20, 2006
Start date
May 2006
Primary completion
Jul 2009
Completion
Jul 2009
Results posted
Jul 16, 2010
Last update
Apr 6, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin

Start the discussion